click enter text
navig healthcar webinar
recess point potenti posit
return like post de-rat estim end
recommend avoid risk macro event
longer unforecast think trade war govern
healthcar posit overweight sector given
defens characterist modest downsid risk estim
reason rel valuat potenti posit price
power strong return capit
mco w/ slight posit bia rx suppli chain
distribut also increasingli cautiou life scienc
top smid cap pick iclr rel lh wcg
rate upgrad outperform
outperform
rate downgrad under-perform
under-perform
word wisdom
end secular winner ultim prevail
rais qualiti bar
dont ignor macro backdrop
ok short becom great short tough market
awar factor exposur
last two materi correct coincid
larg cap drug tend safe biopharma
consum expos tool med suppli non-
slide begin next page
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
navig healthcar
last page report import disclosur regard stock report
tabl content
lesson learn
healthcar polici remain focu
macro level view healthcar point reason fundament
posit surviv thrive
remain challeng odd recess remain
ed highlight synchron global slowdown point oversold condit advis remain defens
global growth prospect deceler end amid rise fear recess reduc growth outlook
fed less dovish stanc rate hike impli hike like put downward pressur multipl
inflat expect also trend higher global still quit subdu absolut basi
high volatil due tighten geopolitical/trad uncertainti unforecast also continu pressur p/e
evr ep st impli revis due slower growth partial off-set buyback
bulk neg revis expect come argu continu defens posit
model price-to-earnings vs trail end year histor median ntm
price-to-earnings support us growth show sign dip recess keep pe within rang
risk pace fed rate hike expect hike trade war escal
overweight healthcar overal attract sub-sector behind growth
primarili due strong price power insul slow growth modest ep expect
backdrop market rebound place eco activ firm potenti larg declin make worth risk
time surviv thrive recommend stay defens
lesson learn
start promis end macro bloodbath
prove turbul year fundament invest trumpd polit macro uncertainti
senat
bond
market sell
sell
earn
instabl
ad tariff list
concern
china
speak
p/e correct notabl ev ebitda remain somewhat elev focu leverag increas
given defens natur complex less ep downsid select valuat appeal
institut remain decidedli split healthcar posit
hedg fund taken defens approach move overweight sector expens
mutual fund remain underweight like increment buyer expens financi
devic mco biotech remain debat
hf increas biopharma exposur also increment hide mco devic
mf taken cro dental exposur continu favor devic tool
lesson learn
lt concern industri structure/margin marri nt deterior thing get pretti ugli quick
exampl pharma distributor gener deflat remain elev idiosyncrat challeng aros cordi
pharmedium uk/canada led de-rat valid fear lt econom disrupt
deflat gross net bubbl despit mani risk show sign truli manifest
exampl despit multi deterior softwar centric book pend threat larg tech
new competit legaci vendor held cern warn outlook hit group broadli although
sometim lt risk actual start manifest market get distract near term event push fear
termin valu impair backburn despit risk real potenti highli disrupt
exampl dental stock price appear deterior broadli partli due dso growth partli due
transparency/amzn partli due forc competit ftc trial overhang investor mostli distract
anim health spin potenti restructur share re-captur
exampl got thrash lt threat post pillpack despit underli fundament deterior mani
chose focu magnitud nt buy-back led relief multipl least nt
exampl offer order upsid year post new product introduct mask underli deterior
busi hasnt translat profit emerg risk advanc cancer treatment point us
develop countri like box
lesson fundament matter lt nt investor posit skew return
typic relat quarterli volatil believ investor posit influenc nt return
time recal exagger unexplain reaction qs news event all-tim high
sell hard post strong ralli materi thereaft result spectacular move higher
ralli initi guidanc materi st si quit high
ralli near flat post cut massiv si also quit high
send lab tumbl cautionari commentari lh essenti repeat script
drive group even lower long bia group result
ralli poor initi guidanc despit elev pe si also quit high
even lesson learn hope
lesson never time sell top qualiti compound
mani suggest run consensu long stellar
equiti prove doubter wrong superior ep growth high confid manag consist
capit alloc make dd tsr compani tough sell
expect bellyach earli year name yet think pois aid portfolio
almost market backdrop
lesson fundament investor macro volatil tough prepar navig
less accommod fed polit uncertainti brexit itali budget woe trade war tariff hard thing
put model fundament analyst unforecast
translat macro level implic equiti tough gener sort healthcar near imposs time
im sure good answer understand control equiti return
expos macro market import lesson imo
lesson find short hardest part job super import
optimist creatur natur mani us work long world seek winner particularli
find loser especi structur probabl import
spend time think technolog chang industri dynam impair
profit futur
market fill mani lesson complac industri profit got wipe
healthcar like next major sub-sector disrupt job figur prepar
appli learn
defens macro backdrop becom decidedli less unpredict
rais qualiti bar stick consist compound think top manag team
dont ignor macro backdrop less leverag recur revenu capital-expenditure dont mess
inconsist perform evid structur risk
growth may offer initi volatil end secular winner ultim prevail dont scare
pure valuat justifi long term
ok short becom great short tough market go get tough weak suffer
posit still matter short term also awar factor exposur tend exagger
last two correct coincid presidenti elect introduc differ aspect
risk equat im look mco
larg cap drug tend safe biopharma consum expos tool med suppli non-polit
 surviv thrive say
drumrollunveil top pick
downgrad under-perform
proprietari macro model point downward pressur core growth management guid pre macro meltdown
outsiz exposur industri capital-expenditure china merit watch given notabl deceler survey
superior execut help mitig downsid ep valuat like compress rel basi
remain best way express increasingli neg view tool complex broadli
downgrad under-perform
retain neg view dental complex given lt risk margin price competit disintermedi
recent benefit notabl share gain consum high-tech equip set moder revers
spin near complet underli profit like st hurt sotp multipl rang mute pe
expect investor question multipl dispar rx dental distributor delta feel wide
patterson dental upgrad under-perform
recent action manag help remov credit dividend risk offer enhanc financi flexibl
restructur sale forc addit like buttress ep current level despit challeng industri environ
crowd short go near-term improv manag chanc share revers move sidelin
clear bullish remain neg dental broadli prefer express via
upgrad outperform
elev growth pbm launch upsid potenti earn benefit outweigh transit delay
expect visibl servic vertic integr strategi march investor day
blue tradit unit cost advantag challeng new model opportun provid servic partner
upgrad outperform
guidanc de-risk given manag commentari macro survey work suggest organ achiev
superior execut margin front come better like yield potenti upsid consensu estim
multipl discount premium growth compani fear larg scale exagger begin normal
lastlywhat happen recess gulp
comparison perform last bear market shall hide
definit flight qualiti
avoid high debt capital-expenditure poor qualiti
devic suppli cardio capital-expenditure ortho
due privat ownership
look past aid build recess resist portfolio need
head four polici theme influenc hc
medicar
let dig topic detail given like influenc alpha
without congress administr like pursu drug price blueprint
class flexibl dir chang point sale
reimport consid certain case
democrat messag drug price
trump blueprint go far enough
friendli pharma compani
govern negoti drug price part
might produc save without
govern formulari exclud drug
disclosur justif high price hike
new enforc agenc identifi price
goug impos fine
allow import cheaper drug abroad
still come
share rebat patient
pharmaci point sale part
revis anti-kickback harbor
rebat medicar commerci
move part drug part
specif promot gener
drug price could best issu
bipartisan legisl trump eye
trump hous major leader pelosi
singl drug price common ground
trump voic support leverag
govern negoti power bigger rep
senat major limit factor
bipartisan signal senat financ committe
broad bipartisan support creat act
address delay tactic gener complet
lawsuit rule creat nois like overturn
unconstitut without tax penalti said
entir insever unconstitut
rule stay appeal process statu
quo remain near term
without immedi threat rep defens
healthcar congress unlik interven
view overhang time final resolut
rather question outcom revers like
ultim decis like overturn
sever question intent clear
case sinc congress remov mandat
penalti deliber leav rest intact
could overturn stand ground
think like scenario circuit court
overturn decis favor
scotu rule could stretch timelin
event think minimum justic robert
decis vote uphold time
exposur coverag
ep exchang medicaid expans
mitig factor hypothet full repeal
direct exposur exchang live medicaid
expans also neg mco
medicar advantag rate cut ff pariti
none republican repeal/replac bill
restor medicar advantag hospit rate cut
headlin risk medicar bark bite
singl payor rhetor could increas elect polit hurdl still remark high
healthcar view win issu democrat midterm support medicar could
becom litmu test crowd presidenti primari race
republican frame medicar threat exist medicar beneficiari ration healthcar
medicar none doctor hospit provid like becom vocal opposit
given like polit backlash cost disrupt real attempt implement much dramat
system chang attempt view singl payor rhetor headlin risk
republican gain make senat map harder democrat lessen risk single-payor legisl
govern reli mco integr deliveri system value-bas care model control cost
medicar advantag realist provid face hypothet pricing/margin risk
chang
mind told would
give govern much
control healthcar
ensur healthcar
basic right
reduc role privat
protect pre-exist condit short-term
junk plan expand trump administr
expand medicar elig buy-in age
could also lower risk profil
nation reinsur program help stabil
increas premium subsidi exchang
three small state vote expand medicaid other could follow suit
voter approv expans id ne ut
expans ks prior governor veto wi
expans issu close race
includ fl governor tx senat
lawsuit uncertainti could barrier
requir enrol impact modest
acut hospit bed expans opt-out state
broader scrutini healthcar price remain major possibl
focu healthcar cost could acceler possibl broader push price transpar
healthcar cost top consum feder budget issu recent scrutini drug cost could
extend broadli healthcar price
propos legisl restrict balanc bill surpris out-of-network charg could first step
high-deduct penetr may slow shortcom patient healthcar shopper could
address motiv amazon/berkshire/jpm jv also push price transpar
bigger deficit tax cut higher spend increas risk futur budget reckon could affect
healthcar spend littl polit appetit address deficit near term
gradual value-bas care transit continu hh sec will push harder
predecessor look return mandatori bundl
cost remain top hc issu voter across parti
healthcar major factor futur feder deficit
macro level view healthcar point
util evercor heat map point stabl environ
coverag type age gallup
stabl
mix outlook regulatori
consum price
commerci price
commerci price
pama impact
price flat
brand/specialti hsd
gener deflat hsd ldd
brand/specialti m-hsd
stabl price line
trend stabl
price elev due tariff
macro may pressur
commerci price stabl
increment pama
price flattish ftc june
brand/specialti msd
gener deflat stabl msd
pharmaci
wholesal impact big
continu favor case mix
advantag competit margin
support reimburs
cancer diseas
nmr/mass spec clinic
stage market develop
modest tam earli
margin heavili depend degre price eros mix
pressur fe
eros off-set cost
cut mix shift
mix disinfl re-
margin partial off-set
margin expans
price hw off-set
cost takeout
price pressur
driven new product volum base
leverag consist consolid
posit price new product
remain ration
price stabl cost
group face scrutini
declin due
molecular mix
 acuiti continu
buyback moder ex
neutral
neutral
neutral
neutral
moder high
moder high
moder high
payment model moder high
neutral posit
topic impact lst sector
tool perform
translat
lsd msd
hsd ep
topic tool tend outperform unless recess
pend growth slowdown reason paus concern particularli given china epicent
howev investor surprisingli complac recent volatil sector act almost defens
topic increas bia recur aid volatil
cyclic less pronounc tool immun synchron slowdown
life scienc improv environ key focu countri plan
china macro evercor isi
tool taken advantag mega trend region reliant china growth us
tool china exposur revenu
macro indic point notabl slowdown w/ industri market like exhibit far sensit
long term outlook remain construct slowdown amid tariff uncertainti like pressur core
mm hw expect off-set mitig
action
hw mm da revenu
wat/qgen/mrk de meaning impact
topic biopharma still like parti rowdi
biopharma growth white hot sinc
inflect mainli relat biotech fund reduc appetit ipo could moder growth msd
mo lag fund tool growth
mean prem/ disc float price initi offer rang
topic consolid like heat valuat correct
tool show savvi buyer downturn favor valuat provid ampl opportun
given b/ recent pullback like acceler w/ potenti strateg deal
capac market cap
proprietari macro model point core growth deceler
core take averag assum similar trend
core assum lei decemb continu year
histor multipl compress growth deceler lead precari setup tool
tool current price expect slowdown group challeng
topic impact mco
visibl
translat
uncertainti
multipl
long out-performance pullback peak risk-off positioning/macro factor plu polici overhang
multipl peak still lt averag
manag care multipl expand meaning past year structur chang
brief histori multipl
previou multipl peak due higher margin top underwrit cycl
trough multipl due confluenc hc reform debat financi crisi cost trend upward inflect
multipl gradual expand implement minim disrupt govern busi drive growth
multipl peak sever year favor cost trend consist dd ep growth ahead tax reform boost
multipl contract year-end due macro factor posit judg rule unconstitut
mco still deserv p/ multipl
above-market double-digit ep growth earn diversif less commerci exposur gov servic revenu
factor mitig potenti neg underwrit cycl minimum profit cap secular pressur cost trend
polici risk/uncertainti lawsuit medicar rhetor expect presidenti elect
polici nois creat volatil multipl
neg headlin end healthcar polit spectrum actual chang unlik
heat start
disrupt
medicar buy-in
realist possibl
suspend
set return
bipartisan support
delay repeal
could best bet
repeal decis weak
legal merit like
think resolut
like happen year
first appeal court
level scotu
could drag
rough math suggest overal profit pool sustain singl payor scenario mco take risk spend
margin assum low end current rang govern busi
cover live aso risk
uninsur gain coverag remaind
fundament still posit w/ visibl particularli strong
trend continu come expect
non-profit rbc recov peak
ci point overal
consist ration price dynam
pocket aggress price alway
non-profit reserv rebound low
still past underwrit peak still face
uncertainti exchang
adv benefit get competit
margin support step reimburs
sustain tax reform benefit still key
question sg reinvest provid cushion
de-risk mco
nearli compani provid guidanc initi commentari line expect
mco alreadi provid good visibl earn
expect alreadi high growth due follow tailwind
commentari guidanc
consensu time
slightli consensu
strong medicar advantag rate expect enrol growth
normal flu histor sever season last year
addit manag commentari cost trend setup appear favor
limit view current year mco essenti project two year
inflat price premium summer follow year
downward cost trend guidanc revis alreadi posit
indic next year
downward trend revis far creat posit setup mco
note ep vs initi guidanc base guidanc ye cost trend base cost trend
 pipelin vertic integr small horizont deal
acquir
acquir banmdica
acquir dmg
stake knd
acquir healthsun
acquir
wcg acquir meridian
deal
acquir
acquir fide
acquir abco hc
acquir aet
acquir america
stake
ci acquir esrx
acquir sound
mco hospit perform past recess
mco hospit outperform
mco under-perform hospit
factor consid recess bear market
mco cyclic defens secular winner
benefit rise rate via invest incom
although commerci enrol may decreas
medicar advantag insul econom
option could limit cobra loss recess
mco under-perform
still risk lessen min profit cap
decreas non-profit market share
earn diversif govern servic
hospit face cyclic risk secular pressur
elect procedur due financi burden
higher unemploy lead self-
medicaid pay less per admiss
commerci insur impact margin even
shift neutral volum
volum outlook posit vs
price also favor skew
current futur expect inpati admiss growth
would categor growth outlook rev/adj admiss next
month scale weak/neg strong growth
strong case mix main contributor
would categor growth outlook patient acuiti case mix
next month scale weak strong expect
concern includ labor reimburs pressur
open-end question biggest challeng
hospit face next year
labor cost grow faster revenu
staf includ nurs labor shortag
flat declin reimburs despit rise labor
polici clariti mostli uncertainti around
competit includ outpati shift well
increas competit provid
urgent care center larger health system
hospit wage growth acceler market
though companywid swb growth stabl
economi near peak employ wage pressur increas still manag rang
across acut care space wage growth
higher year ago
howev categor trend
stabl acceler
acut side would say today wage growth probabl
kind rang think talk year ago
probabl would like
labor trend pretti stabl rang
term growth averag hourli rate look across
hospit leader continu drive improv effici swb line
even year-over-year wage rate increas approxim
wage rate hover around
multipl compress support fundament
multi-year out-performance multipl fallen
peak risk-off positioning/macro factor
recent nois also includ lawsuit like singl
payer rhetor presidenti elect
howev mco stronger posit previou
cycl merit multipl lt histor averag due
above-market double-digit ep growth earn
diversif less commerci exposur gov
 servic revenu factor mitig
potenti neg underwrit cycl minimum
 profit cap secular pressur cost trend
fundament still posit w/visibl strong
trend ratio price commentari point
stabil head
tailwind includ strong rate hif interest rate
outlook alreadi larg de-risk due recent
guidanc posit commentari call line
better expect
even econom downturn mco cyclic defens
due insul gov busi unemploy offset
medicaid increas invest incom rate increas
new coverag option avail last downturn
could limit initi loss cobra recess
could benefit lower core util
nois around mco nois
think legal merit lawsuit
weak expect decis
revers appeal view broadli echo
think like circuit
shift toward medicar advantag
feasibl ff medicar insur
quick math show industri profit pool
sustain singl payor market manag care
hospit nt setup construct lt risk remain
signific volum price improv
evercor isi hospit survey show optim around
hospit execut expect improv admiss
volum strong acuity/pr rel histor
result consist public hospit compani
commentari around strong continu price
economi near full employ wage pressur
increas still manag level
howev hospit face greater fundament risk even
econom downturn mco still face secular pressur
value-bas care shift
topic impact rx suppli chain
type
evolut
 result
begin stabil
translat
revenu
topic drug price appear stabil volatil period
earli indic jan price hike brand encourag gener also show sign normal
disappoint brand inflat manag disti
littl impact expect pbm drug store
ep impact declin brand
stabl drug price benefit
pharmaci time
mismatch rate paid drug
purchas pbm reimburs
separ reimburs rate pressur
pharmaci continu bp
pbm profit depend gap
gross net price movement net price
increas slower gross price growth could
earli strategi emerg vertic deal close
in-stor clinic key compon improv health
outcom drive lower cost
staf nurs practition conveni
hour help lower er visit increas care
chronic ill
telehealth remain under-penetrated way help
manag chronic ill lower price point
store also experi replac front-end
merchandis varieti healthcar servic
engag point subject threat
drug store experi hc servic pilot
optometri
audiolog
topic reimburs pressur like worrisom
pharmaci like remain pressur
amazon enter pharmaci via pillpack share
due mainli reimburs pressur mix shift front end end gener wave
tangibl headwind concern present
pharmaci margin sieg weaker front
narrow network dir fee etc mix shift within
pharmaci specialti less profit gener
threaten front end gener
pharmaci via pillpack small grow
pharmaci fight back via swap front end floor
space healthcar servic see prior slide provid
amazon threat like overbak headlin risk
exist true threat like emerg time
tradit pressur busi howev unlik abat
topic impact dental specialti distribut
continu
much room
go
improv
sign crack
translat
continu
align
topic price like remain pressur
amazon litig open crack price
three dental distributor benco
subject ftc complaint alleg
conspiraci restrain price competit
three also settl class action suit septemb
deni wrongdo relat price fix
addit amazon enter dental market year
ago garner l-msd market share
amzn share gain larg come
expens smaller distributor howev
compani serv degre price check
market increment transpar
use least
purchas suppli
suppli purchas
gross margin begun show sign strain
could happen
dentist awar lawsuit high half
believ result improv price
awar high even among small group dentist
high-margin distribut custom price
discount group caus high decrement
ftc suit monetari penalti like
compani enter ftc complianc program
prove competit natur market would put
pressur price start summer
though product access grey market issu continu
provid check growth
topic dso shift like sustain pressur dental margin
dentistri remain domin small practic
doctor much along consolid
dental margin high end distribut
us censu statist us busi evercor isi
topic equip growth remain bumpi given macro despit id
inconsist growth channel inventori issu
equip purchas intent tick still norm
catalyst id march boost equip sale
danah dental spin bring new cap new idea
biannual id chanc new product launch
dont see major new categori
horizon expect see
progress product/system integr
applic print
also expect continu steadi uptak x-ray
machin intraor scanner
id gener bring larger equip boost eu
sale na sale benefit normal
distributor inventori level well slight id bump
spin danah dental segment bring new
interest/money space well direct sale
approach key tenet db toolkit challeng us
dentalco work integr dispar offer
launch new product sometim play catchup
db playbook improv oper margin bp
nobel though total segment hit uneven revenu
dentalco abl rais om post
initi phase invest
effort also gener improv revenue growth
see acceler lsd
topic still domin clear align
remain undisput leader align
still incred larg w/ldd penetr
what
align roll focus ortho practic
feedback good far
like bring gp roll-out
employe excit invest straumann
sale peopl use bracket/wir effort hard time
convert align addit focu
visit requir start case new practic
lack enough patient data complet case
convinc ortho mani case
gradual launch plan start australia test
case iron wrinkl etc
rais mm bn valuat octob
result next catalyst
investor zero america asp
expect y-o-i declin
declin wake bear
lead increas fear competit
bull asp declin better
tick box improv
dental highlight
topic impact
make
sens ever-
phoenix emerg
space dead
hit
translat m-
growth l-
topic dont rebound base anytim soon
ehr market cont grow slower rate
year ago report forecast ehr market grow
howev market expand incent pass
signific issu aros inferior technolog
growth materi slow like
realist rang best
rip replac market ehr switch
continu somewhat stabl due hospit
physician dissatisfact current system higher
cost product loss etc unlik activ
year ago
signific issu current system
biggest issu notabl buzzword
make progress slowli system
cant easili exchang health data one anoth
complex report guidelin cmss
ehr incent program often oner
slow clinic workflow
lack usabl function data error system
mani studi show current technolog
intuit navig
market need competit innov
obviou lack innov healthcar
technolog current ehr antiqu natur
healthcar whole increment concern
furthermor incumb epic etc
control market increas competit
necessari see technolog innov seen
industri
need polici forc ehr vendor
interoper data avail use
third-parti vendor fhir attempt
need better way model analyz clinic data
reduc complex semant help
develop innov easili design better health
need happen ehr market reviv
usabl need improv
voic gesture-bas interfac vs type
googl alreadi pilot
ai within ehr need play bigger role
ai algorithm need transform scrape data
suggest diagnos patient
stronger demand better service/qu
consum need better educ
understand technolog optim
workflow demand softwar
vendor purpos databas
ehr vendor contract win loss activ slow materi
larg contract activ win declin sinc epic/cern lead pack request tracker
sourc evercor isi kla report healthcareitnew ehrintellig american hospit directori vendor custom websit
capital-expenditure survey result continu fall prioriti
robot spine mazor globu
robot spine mazor globu
expect capit expenditur spend follow
hospit challeng emr/connect smaller area concern
would say biggest challeng face hospit next one two year
respond highlight rise cost
recent court rule texa
unconstitut increas
said rule appeal
dont expect see impact
next year
labor concern match
interestingli connect seen
smaller area concern match trend seen
industri
topic popul concept like continu evolv
us market best slow
increas healthcar expenditur rise need vbc
effect diseas manag drive growth market
isnt market ramp like initi thought
declin averag vendor revenu per life manag
fall trend market start scale
provid look manag lower acuiti live
aco take downsid risk well upsid risk
dont particip expect
slower adopt new system procur
uncertainti around delay decision-
threat reform rais market uncertainti around
make purchas
signific detriment impact vendor revenu
catalyst market need inflect
cost patient outcom fundament critic
democrat take back control hous
anoth wave wider healthcar spend trend
drive anoth rip replac market ehr
erp system consolid smaller
practic larger hospit network idn
push meet qualiti target continu drive
growth report optim
advanc ai take administr
market burden autom outreach
growth internet thing help health system
access analyz new patient dataset medic
achiev success popul health health system
need understand cost patient outcom
key question health system ask much
cost system increas patient
clinic outcom one unit measur
pop health equat return engag
clinic outcom achiev total patient invest
patient health health system
popul player watch
topic budget direct toward data ai demonstr roi
biggest driver technolog spend hc
area see increas spend data analyt
recent hc demand survey gather vbc initi
follow patient engag care manag initi
major driver technolog spend
patient engag care
cybersecur ransomwar
data analyt
internet thing iot
lack enterpris readi new technolog one biggest headwind growth hc spend
lack enterpris
readi new
roi new
maintain
cyber secur
risk associ
competit rise particularli non-tradit player hc like hc spend
focu data analyt ai increasingli critic
topic impact clinic lab
lh go gain
bottom lab
make sens
translat
topic like price declin
thought recent gao report impli lab price go
recent gao report rais number point around lab possibl overearn via bundl panel test exploit
system new rate possibl lead billion excess payment
one point made around bundl payment idea lab bill certain panel individu test vs
think logic somewhat flaw lab get paid la cart price compon given test
use variou code old methodolog use atp code
possibl could lab intent mis-bil gao estim medicar expenditur could
increas much bn seem excess
high level point rais seem bizarr us learn scope author chang anyth
overli concern moment
new multisourc contract net posit lt
price pressur alreadi
announc like announc contract
florida bcb think nt dilut
exampl math recent horizon bcbsnj
contract open multi-sourc ep
accret dilut lh near
howev net net posit lt
lab despit nt dilut achiev
share gain time vs regional/indpt lab
expect trend health plan open broaden
access better valu laboratori servic continu
pama pressur like peak normal
pama cut kick cut
compound
cut compound rate paid
reduct rate alreadi
subject cut
believ reimburs pressur begin
moder start howev
like reach peak
howev think given cut well-
known compani abl buffer blow
via unh/aet contract addit contract
open organ volum gain prefer low-
topic share gain eventu materi given advantag
ye pama price cut catalyst consolid
smaller lab disproportion impact medicar
pama trigger outreach lab consolid
outreach acquisit lead pl agreement and/or
lower rate fee schedul
hospit
remaind
rest industri absorb
disproportion amount cut
lab execut acceler
dgx/lh current share market
lh larg portion independ lab
segment captur
topic contend unusu string headwind prove tempor
feel emerg issu
patient respons ar- tempor dgx-
believ compani like mis-model
assumpt involv revenu accrual
process rate denial
odd develop seem irrat bear
cost insourc given pressur independ
labs/hospit like unsustain
believ lh ransomwar attack juli
play big part work order
either canceled/refund delay
believ may offer form
physician waiver send test order
without charg prepar contract
strategi would help figur
opportunist locat garner interest ahead
shift volum ahead contract follow
pattern normal
feel clinic lab
last month weve seen clinic lab go
teen ebitda multipl
busi histor experienc
ton volatil rel rest servic complex
bumpi month say least
near term headwind certainli ponder
remain confid lt thesi continu
vertic integr via step outreach pl
deal lh/dgx abil posit
right end industri shift toward scale low-cost
provid broad rang servic
feel valuat
lt thesi stick increment volum
health plan contract well step outreach
 pl deal turn aid margin oper
incom growth lead shift ep growth
long term
risk profil slightli higher near-term
headwind ep growth still feel confid
hsd ep growth modest organ growth
continu uptick dividend tsr
growth rang
look peer tsr rang
group trade averag price-to-earnings
ev/ebitda impli signific premium
topic impact med-tech sector
med-tech outlook remain solid high visibl amidst sea macro uncertainti
translat
msd hsd
dd ep
myth extend
downturn
util lead indic jolt survey bode well util
healthcar jolt lead indic correl well ss hospit admiss post crisi remain robust
prop survey in-pt admiss accel
hospit c-suit
overal surgic volum growth stabl
price slight uptick reimb pressur off-set mix benefit
show slight incr reimb pressur
bospit ppi see big gain point mix benefit
colon rectal surg
mrg data show larg stabl
ortho hip knee volume strong asp declin stabl
fred bl mrg
capital-expenditure budget stabl upaca uncertainti swing factor
respond ask capital-expenditure growth expect repons spend level
gener match hospit med-tech compani commentari provid baselin
gaug expect
prop survey hospit capital-expenditure budget stabl capac exp dx inst imag top prioriti
respond ask rank top
spend area aggreg
prop survey hospit labor reimburs regul cite major area hospit challeng
respond highlight rise cost labor
recent rule texa unconstitut
increas uncertainti
said rule appeal dont
expect see impact next year
labor concern match jolt data job
regulatori uncertainti could swing factor
come capital-expenditure spend price pressur
evercor isi
innov remain robust support healthi spend
product launch
gain oppti mitraclip fda label exp fmr lvad
ew risk fda approv pascal launch eu
meso fda approv enrol complet brain
halcyon adopt china quota upsid bravo
 spend remain robust hsd rate med-tech
coverag highest name ew
 rev
evercor isi
futur greenfield oppti vs industri risk skew oppti
mitral valv opportun tmtt renal
denerv htn penetr robot
ttf indic expans cancer penetr
diabet low cost easi use
on-going ew vs litig lead injunct
headlin risk penetr robot surgeri
eg nrjm articl cite risk cancer seed
regress show ew premium vs group average discount
current ep vs estimate ep growth
seem expens ew tad trend-line
rel cheap
trade p/e ev/ebitda
 use p/e ratio
rel valuat
methodolog back dcf
note organ growth estim ep evrisi estim
valuat myth med-tech expensivenot realli
sinc financi crisi earn averag market
med-tech earn expect growth doubl digit vs msd market
isi view ep
growth vs st
rel market med-tech valuat dont appear egregi basi given robust ep growth
premium
med-tech expect grow ep
min risk vs estimate
think superior earn
growth justifi rel premium
pt also back
valuat o/p recess make med-tech safe
med-tech price-to-earnings premium vs gener within histor rang
spread vs pharma
debat histori suggest
o/p uncertain period
note med-tech constitu includ ew bcr stj
note ii pharma constitu includ
posit
hs sub-sector heat map limit area deploy capit
remain bias single-stock select sub-sector screen notabl better other
return capit
return capit
return capit
return capit
return capit
return capit
return capit
return capit
return capit
return capit
tool exagger devic mco remain elev suppli chain screen inexpens
drug stock near histor discount extrem vs
price-to-earnings premium discount
major pharma price-to-earnings premium discount
spec pharma price-to-earnings premium discount
dental price-to-earnings premium discount
med-tech price-to-earnings premium discount
tool dx price-to-earnings premium discount
price-to-earnings premium discount
provid price-to-earnings premium discount
suppli chain price-to-earnings premium discount
roll must name
largest potenti area risk remain question
clariti trade march stuck volatil macro environ
remov unforecast event could prove major uplift multipl growth
avoid recess year row fall victim sentiment
market economi defi odd decad make expans notabl
learn elect field partisan polit influenc hc
nois unlik disrupt emerg candid offer headlin risk
year make progress drug price reform busi usual
much come far blueprint bipartisan support suggest clear yet
face disrupt risk entiti wont sustain elev buyback
luck
hope found present insight highli differenti
seek approach job sell-sid analyst slightli outsid norm
want back-up data behind analysi pleas email
question desir discuss outlook detail pleas reach
help look forward work everyon
articl articl
time dissemin januari
matthew nicolai primarili respons prepar research report attest follow view opinion render
research report reflect person view subject compani issuer part research analyst
compens directli relat specif recommend view research report
